Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMAB027 in recurrent advanced ovarian cancer
NCT02054351Phase 1Completed
- Sponsor
- Ganymed Pharmaceuticals
- Start
- Feb 2014
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of imab027 in ovarian cancer, sponsored by Ganymed Pharmaceuticals. Primary endpoint: Safety and tolerability at 24 months. Started Feb 2014; status: completed.
02
Drugs
imab027
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02054351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02054351.